Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Immunotherapy for lung cancer
What immunotherapy for lung cancer is, how immune checkpoint inhibitors target PD-1, PD-L1 and CTLA-4 pathways, what clinical evidence shows for advanced non-small cell lung cancer, approximate costs in Turkey compared with the UK, US and Germany, how infusions compare with chemotherapy and targeted therapies, treatment schedules, immune-related side effects and how to choose an accredited cancer centre.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Immunotherapy for Lung Cancer
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Immunotherapy for lung cancer in Turkey: what it is and how it works
Immunotherapy for lung cancer is an advanced oncological treatment that empowers the patient's own immune system to recognise and destroy malignant lung tumours. Unlike conventional chemotherapy that acts directly as a cellular toxin, immunotherapy works by disabling the molecular shields that cancer cells use to hide from immune detection. In Turkey, accredited cancer centres provide immunotherapy for lung cancer Turkey programmes for patients with advanced non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (SCLC). For an overview of international oncology care, see our guide to oncology treatments in Turkey.
Immunotherapy has reshaped the standard of care for locally advanced and metastatic disease, offering durable tumour control where older regimens provided limited survival benefit. This guide explains how checkpoint inhibitors work, what the evidence shows, international costs, recovery timelines, potential side effects and how to choose an accredited hospital.
How do immune checkpoint inhibitors treat lung tumours?
The immune system uses natural checkpoints to stop T cells from attacking healthy tissue. Lung cancer cells hijack these safety pathways by displaying surface proteins that bind to T-cell receptors, switching off the immune response. Checkpoint inhibitor drugs are laboratory-made monoclonal antibodies that block these deceptive signals:
- PD-1 inhibitors: Drugs like pembrolizumab and nivolumab block the PD-1 receptor on T cells, restoring their cancer-fighting ability.
- PD-L1 inhibitors: Agents such as atezolizumab and durvalumab bind to PD-L1 on tumour cells, keeping immune pathways open.
- CTLA-4 inhibitors: Medications such as ipilimumab stimulate T-cell activation within lymph nodes for a broader immune response.
By blocking these checkpoints, patient T cells infiltrate and destroy tumour tissue. For more on biological therapies, see our guide to immunotherapy.
Does immunotherapy for lung cancer work? What clinical evidence shows
Major phase III trials reviewed by ESMO, ASCO and NICE confirm that immunotherapy significantly extends overall survival in selected lung cancer patients. For tumours with high PD-L1 expression (TPS ≥ 50%) and no contraindicating driver mutations, front-line immunotherapy substantially outperforms standard chemotherapy in both duration of response and median survival.
Clinical evidence also highlights important limitations:
- Response rates: Single-agent response rates range between 15% and 25%, rising to 40% to 60% when combined with chemotherapy.
- Durable survival: Patients who respond often achieve long-term disease control, with meaningful proportions surviving beyond five years.
- Pseudoprogression: In 3% to 5% of cases, tumours temporarily swell on early scans due to immune infiltration before shrinking.
Immunotherapy does not work for every patient and is not a guaranteed cure, but it provides proven long-term tumour control.
Immunotherapy for lung cancer cost in Turkey compared with the UK, US and Germany
The cost of treatment depends on the specific drug prescribed, patient weight or fixed dosing, cycle frequency and whether chemotherapy is given concurrently. In private hospitals across the UK and the US, substantial drug mark-ups and infusion fees create heavy out-of-pocket expenses. Hospitals in Turkey provide the same branded oncology drugs at lower institutional overheads.
| Country | Approximate cost per cycle |
|---|---|
| Turkey | €2,500 – €5,500 |
| United Kingdom | €4,500 – €9,500 |
| United States | €9,000 – €22,000 |
| Germany | €4,000 – €8,500 |
Factors affecting the overall immunotherapy for lung cancer cost include the drug regimen, pre-infusion blood tests, follow-up CT or PET-CT scans and supportive medications. A combination protocol carries a higher immunotherapy for lung cancer price than monotherapy. Hospital packages typically cover oncologist fees, day-case infusion suite charges and basic monitoring.
Immunotherapy, chemotherapy or targeted therapy: which approach fits?
Choosing systemic therapy requires accurate pathology and genetic profiling. Lung cancer encompasses biologically distinct subtypes requiring different treatment mechanisms.
| Treatment type | Best suited to | Typical limits |
|---|---|---|
| Immunotherapy | High PD-L1 expression, advanced NSCLC, or combined with chemotherapy | Does not work for every patient; takes time to show response; immune-related toxicities |
| Chemotherapy | Broad range of lung cancers, rapid disease progression, small cell lung cancer | Attacks healthy dividing cells; causes nausea, hair loss, fatigue and cytopenia |
| Targeted therapy | Tumours with actionable driver mutations (e.g. EGFR, ALK, ROS1, BRAF) | Ineffective without matching genetic mutation; resistance often develops over time |
Tumours with driver mutations (such as EGFR or ALK) respond best to oral targeted drugs; see our guide to targeted therapy. Where no targetable mutation exists, combining immunotherapy with cytotoxic drugs is common; read our guide on chemotherapy.
Who is an eligible candidate for lung cancer immunotherapy?
Eligibility depends on molecular biomarkers, tumour stage and overall fitness. An oncologist evaluates the following factors before recommending treatment:
- PD-L1 expression: Biopsy tissue is tested by immunohistochemistry. A Tumour Proportion Score of 50% or higher supports first-line monotherapy, while lower scores usually warrant combination therapy.
- Driver mutation testing: Tumours are screened via next-generation sequencing for EGFR, ALK and ROS1 mutations; if present, targeted therapies take priority.
- Performance status: An ECOG score of 0 to 2 indicates sufficient physical reserve to tolerate systemic therapy.
- Autoimmune conditions: Patients with active autoimmune diseases (such as Crohn's disease, lupus or multiple sclerosis) or those on systemic steroids require careful evaluation due to heightened toxicity risks.
What happens during an immunotherapy infusion cycle?
Immunotherapy is an outpatient day procedure that takes two to three hours from arrival to discharge:
- Pre-infusion blood tests: Full blood count, liver enzymes, kidney function and endocrine panels (thyroid and cortisol) are checked before each infusion.
- Oncologist review: The medical oncologist examines the patient, reviews test results and confirms medication release.
- Intravenous administration: A specialised nurse administers the drug through an intravenous line or port. The infusion takes 30 to 60 minutes via an automated pump.
- Post-infusion observation: The patient is monitored for 30 to 60 minutes for acute allergic reactions or fever before returning to their hotel.
Immunotherapy before and after: scan results and evaluating response
Response to lung cancer treatment is evaluated with cross-sectional imaging rather than physical before-and-after photographs. Contrast-enhanced chest CT or PET-CT scans are performed every 6 to 12 weeks to assess disease status using RECIST and iRECIST criteria:
- Complete response: Disappearance of all target lesions on scans.
- Partial response: At least a 30% reduction in tumour measurements.
- Stable disease: Tumour growth is halted, preventing disease progression.
- Pseudoprogression: In 3% to 5% of patients, an initial scan shows temporary tumour enlargement caused by T-cell infiltration rather than genuine growth. If the patient feels well, treatment continues and status is confirmed on a follow-up scan.
Ask the coordinator for anonymised radiological case reviews showing realistic response patterns.
Treatment schedule, travel to Turkey and recovery between cycles
Infusion schedules run every two, three, four or six weeks depending on the prescribed drug. For an initial cycle, plan to stay in Turkey for five to seven days: arrive 48 hours early for baseline blood tests and imaging, receive the infusion, and remain for two to three days of post-treatment monitoring before flying home.
Day-to-day immunotherapy for lung cancer recovery between cycles is substantially easier than recovery from cytotoxic chemotherapy. Most patients do not lose their hair or experience severe nausea. Mild fatigue is common and usually improves with rest and hydration. Subsequent cycles can be completed through repeat visits to Turkey or via shared-care arrangements coordinated with your oncologist at home.
How to choose an oncology centre in Turkey and questions to ask
When travelling for cancer treatment, select hospitals accredited by JCI or certified by the Turkish Ministry of Health with dedicated thoracic oncology teams and on-site intensive care. Red flags include guarantees of cure, quotes without specific drug names and doses, and clinics that do not offer aftercare communication. Learn how our process works and submit your pathology reports via our free quote page for medical review.
Key questions to ask the clinic:
- Is my treatment plan reviewed by a multidisciplinary tumour board?
- Which specific drug, dose and cycle frequency do you recommend?
- What emergency care is available if I experience an acute reaction?
- How will my treatment records be shared with my home oncologist?
- Who do I contact if side effects arise after I fly home?
Hospitals with Oncology in Turkey
Frequently asked questions
Immunotherapy for lung cancer uses monoclonal antibody medicines to help your own immune system recognize and kill cancer cells. Rather than directly poisoning cells like chemotherapy, it blocks checkpoint proteins such as PD-1 and PD-L1 that tumours use to hide from immune T cells, allowing your body to mount an effective anti-tumour response.
Yes, clinical trials show that immunotherapy significantly extends survival in patients with advanced non-small cell lung cancer, particularly when tumours express high PD-L1 levels. It does not work for everyone, with response rates between 15% and 60% depending on biomarkers and whether chemotherapy is added, but responders often experience durable, multi-year disease control.
Approximate costs in Turkey range from €2,500 to €5,500 per infusion cycle, compared with €4,500 to €9,500 in the UK and up to €22,000 in the US. Total expense depends on the specific drug, patient dosage, frequency of cycles, diagnostic imaging and whether chemotherapy is given concurrently.
Before-and-after results in lung cancer are evaluated through CT and PET-CT scans rather than outward photographs. Scans typically show tumour shrinkage or stable disease after two to three months. In some patients, initial scans show temporary swelling from immune cell infiltration, known as pseudoprogression, before tumours begin to regress.
Chemotherapy attacks all rapidly dividing cells, causing side effects like hair loss and nausea. Targeted therapy blocks specific mutated proteins in tumours with driver mutations such as EGFR or ALK. Immunotherapy stimulates the immune system to target cancer and works best for tumours with high PD-L1 expression lacking targeted driver mutations.
Eligible patients typically have advanced or metastatic non-small cell lung cancer or extensive-stage small cell lung cancer. Biopsy tissue must be tested for PD-L1 expression and screened for driver mutations. Patients need adequate general health and organ function, and those with severe active autoimmune conditions require careful specialist evaluation.
Day-to-day recovery between cycles is generally manageable, with most patients avoiding severe nausea or hair loss. Mild fatigue is the most common side effect and typically eases after a few days of rest. Most patients maintain their normal daily routines between their three-week or four-week infusion appointments.
The intravenous infusion is painless, similar to a standard drip. Side effects are primarily immune-related, occurring when active T cells irritate healthy tissues. Common effects include fatigue, skin rashes and mild bowel changes. Serious complications like lung or colon inflammation occur in a minority of patients and require prompt corticosteroid treatment.
Patients who respond well typically continue treatment for up to two years, provided the tumour remains controlled and side effects are manageable. In consolidation settings following chemoradiotherapy, treatment is often given for 12 months. Some patients maintain long-term disease control even after completing their planned course of therapy.
For an initial cycle, plan to stay in Turkey for five to seven days. This allows two days for preliminary oncologist consultations, blood tests and imaging, one day for the infusion, and two to three days to monitor for acute reactions before travelling home. Subsequent visits are often shorter.
Patient stories